Intrinsiqq
TuHURA Biosciences, Inc. logo

TuHURA Biosciences, Inc. Quality Score

HURA

Compare
Quality0

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-2.5x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-3.5x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
28840662.3%

Heavy dilution above 5%

Capital Structure
0/100
$8M

Positive debt with no FCF to service it

2012
$1794
$0.00
2023
$4.00M
$2.00M
2024
$13.0M
$202542
2025
$4.00M
$502668
TTM
$2.00M
$10.0M
CashDebt
Customize WeightsPremiumUpgrade

TuHURA Biosciences (HURA) quality: score, margins and returns

TuHURA Biosciences (HURA) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is TuHURA Biosciences (HURA) a high-quality business?+

TuHURA Biosciences scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does TuHURA Biosciences's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from HURA's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where TuHURA Biosciences scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 10 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with HURA

CompareIntrinsic value
VRCAVerrica Pharmaceuticals Inc.
$2.74-5.03%40
VYNEVyne Therapeutics Inc.
$12.90-9.35%36
TVRDCara Therapeutics Inc.
$0.99+4.55%20
AARDAardvark Therapeutics, Inc.
$0.92-7.74%10
SLNSilence Therapeutics plc
$19.81+0.00%10
BIOEBio Essence Corp
$0.47+0.00%55
BOLTBolt Biotherapeutics Inc.
$4.91-2.96%15
CVSICV Sciences, Inc.
$0.01-2.00%25

Held by ETFs

HURA is in 1 US ETF. The largest of them, with HURA's weight in each:

Spot a number that looks wrong? Check it in HURA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing HURA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.